- October 04, 2017
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical to Participate in Japan Healthcare Venture Summit 2017
Taiho Pharmaceutical Co., Ltd. will be participating in the Japan Healthcare Venture Summit, to be held at PACIFICO Yokohama, Japan from October 11th to 13th, 2017.
The Japan Healthcare Venture Summit, hosted by the Japanese Ministry of Health, Labour and Welfare, is an event aiming to promote biotech ventures. Exhibition booths, presentations, and business matching meetings are planned during the event. Taiho Pharmaceutical will be introducing a new venture support ecosystem at its exhibition booth, while also taking a part in the matching event.
In June 2014, Taiho Pharmaceutical decided to invest maximum total of 30 million USD in an open innovation biotech venture capital fund, Regimes BioPharma Fund, LP (hereafter “Remiges Fund”) specializing in investments on drug discovery, and have thereafter implemented a collaboration to nurture human resources with assessment abilities and to establish the network in the US/Europe biotech start-up community. Furthermore, in April 2016, Taiho Ventures, LLC, a strategic corporate venture capital arm of Taiho Pharmaceutical, was established with the purpose to invest globally in bio-venture companies and have thereafter accelerated the collaboration with promising start-up companies.
Through the collaboration with Remiges Fund and Taiho Ventures, Taiho Pharmaceutical will attempt to continue delivering innovative new drugs to patients and medical professionals.
Japan Healthcare Venture Summit 2017 Official Website
About Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharmaceutical company focusing on the three fields of oncology, allergies and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan that develops innovative medicines for the treatment of cancer, and is promoting business globally. The company creates quality products that effectively treat a variety of medical conditions in other areas as well. Always putting customers first, Taiho Pharmaceutical also aims to offer over-the-counter medicinal products that support people's efforts to lead fulfilling and rewarding lives.
About Taiho Ventures, LLC
Taiho Ventures, LLC is the corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., established on April 2016. Based in California, Taiho Ventures is a newly established strategic investor looking at early stage preclinical oncology companies as well as platform technology companies for core therapeutic areas of Taiho Pharmaceutical. We will review the wide variety of modalities (both biologics and small molecules) and opportunities mainly in US and Europe. We will also consider the option-type of investments and spin-outs, in addition to pure equity investments.
Information in this news release was current as of the original release date.